Reviva Earnings Reports

Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $6.1 million for the first quarter of 2025. The company's focus remains on advancing its late-stage brilaroxazine program.

Reviva Pharmaceuticals reported a net loss of $8.4 million for Q3 2024. The company is advancing its brilaroxazine program, with topline data from the OLE trial expected in December 2024 and a potential NDA submission targeted for Q2 2026.

Reviva Pharmaceuticals reported a net loss of $7.9 million, or $0.26 per share, for the second quarter of 2024. The company's cash totaled approximately $6.2 million as of June 30, 2024.

Reviva Pharmaceuticals reported a net loss of $7.4 million, or $0.25 per share, for the first quarter ended March 31, 2024. The company's cash totaled $12.0 million as of March 31, 2024. They gained alignment with the FDA on brilaroxazine clinical trials for NDA submission in schizophrenia and expect to initiate the RECOVER-2 trial in Q2 2024.

Reviva Pharmaceuticals reported a net loss of $39.3 million for the year ended December 31, 2023, compared to a net loss of $28.3 million for the previous year. The company's cash and cash equivalents totaled $23.4 million as of December 31, 2023, compared to $18.5 million as of December 31, 2022. The company is targeting a potential NDA submission in Q3 2025.

Reviva Pharmaceuticals announced positive topline results for its Phase 3 RECOVER trial, with brilaroxazine demonstrating statistically significant and clinically meaningful reductions in schizophrenia symptoms. The company reported a net loss of $10.5 million for the third quarter of 2023 and has $5.0 million in cash reserves.

Reviva Pharmaceuticals reported a net loss of $12.4 million for Q2 2023, compared to a net loss of $5.3 million for the same period in 2022. The increase in net loss was primarily due to increased research and development and general and administrative expenses. The company's cash totaled $11.2 million as of June 30, 2023.

Reviva Pharmaceuticals reported a net loss of approximately $6.6 million, or $0.30 per share, for the three months ended March 31, 2023. The company's cash totaled approximately $11.3 million as of March 31, 2023.

Reviva Pharmaceuticals reported a net loss of $24.3 million for the year ended December 31, 2022, with cash and cash equivalents totaling $18.5 million. The company believes its cash will be sufficient to fund operating plans through the third quarter of 2023. Topline data for the pivotal Phase 3 trial evaluating brilaroxazine for schizophrenia remains on track for mid-2023.

Reviva Pharmaceuticals reported a net loss of $3.5 million for the third quarter of 2022. As of September 30, 2022, the Company’s cash totaled approximately $23.2 million.

Reviva Pharmaceuticals reported a net loss of $5.3 million for the second quarter of 2022, with cash totaling $19.4 million as of June 30, 2022. The company is focused on advancing the clinical development of brilaroxazine in the Phase 3 RECOVER study for schizophrenia.

Reviva Pharmaceuticals reported a net loss of approximately $7.4 million, or $0.40 per share, for the three months ended March 31, 2022. As of March 31, 2022, the Company’s cash totaled approximately $23.4 million.

Reviva Pharmaceuticals reported a net loss of $8.5 million, or $0.58 per share, for the year ended December 31, 2021. The company's cash totaled approximately $29.7 million as of December 31, 2021.

Reviva Pharmaceuticals reported a net loss of $2.28 million for the third quarter of 2021. As of September 30, 2021, the company's cash totaled $33.5 million.

Reviva Pharmaceuticals reported a net loss of $2.6 million for the second quarter of 2021. The company's cash and cash equivalents totaled $35.8 million as of June 30, 2021. They closed an underwritten public offering of common stock and warrants resulting in gross proceeds of $34.5 million.

Reviva Pharmaceuticals reported a net loss of $3.8 million for the year ended December 31, 2020. The company closed a merger with Tenzing Acquisition Corp in December 2020 and is planning a Phase 3 study of RP5063 in mid-2021, assuming fundraising goals are achieved.